New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has listed 29 batches of drugs, surgical products, and a pharmaceutical ingredient as Not of Standard Quality (NSQ) in its central drug laboratory report for August 2026.

The findings cover injectables, antibiotics, cardiovascular medicines, antifungal capsules, cough preparations, and dressings.

Several injectable products failed sterility or bacterial endotoxin tests. These include Bupivacaine Hydrochloride in Dextrose Injection manufactured by Themis Medicare, Haloperidol Injection manufactured by Tamman Titoe Pharma, Compound Sodium Lactate Injection manufactured by Paschim Banga Pharmaceutical, and Glycopyrrolate Injection manufactured by Jackson Laboratories. The compound sodium lactate sample also failed the particulate contamination test.

Other injectable products were flagged for different reasons. A Dexamethasone Sodium Phosphate Injection batch manufactured by Cotec Healthcare failed tests including particulate matter and assay. A Rabeprazole Sodium Injection batch manufactured by Martin & Brown Bio-Sciences failed multiple tests, including clarity of solution, particulate matter, pH, related substances and assay.

The list also includes Amoxicillin and Potassium Clavulanate Tablets manufactured by Brooks Laboratories, which failed the dissolution test for amoxycillin; Rabeprazole Sodium Tablets manufactured by Intas Pharmaceuticals, which failed the buffer-stage dissolution test; and Clopidogrel Tablets manufactured by Bactolac Formulation, which failed dissolution testing. Two batches of Itraconazole Capsules, made by Kivi Labs and Azot Life Sciences, were also flagged for dissolution failures.

Drugs and healthcare products that fail to meet prescribed quality standards are categorized as Not of Standard Quality (NSQ). Under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940, a drug is required to comply with the standards specified under the Act and the relevant pharmacopoeial requirements. Failure to meet these standards can result in regulatory action, including product recalls, investigations, and legal proceedings against manufacturers where warranted.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .